Management of pulmonary hypertension in left heart disease

Therapeutic Advances in Cardiovascular Disease

Volumn 7, Issue 3, 2013, Pages 131-151

  Schmeisser, Alexander ^a   Braun Dulleaus, Ruediger C ^a   Schroetter, Hagen ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

management; post capillary pulmonary hypertension; pulmonary hypertension due to left heart disease; transpulmonary gradient

Indexed keywords

BOSENTAN; DARUSENTAN; ENDOTHELIN 1; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL; TEZOSENTAN;

BLOOD VESSEL CAPACITANCE; CARDIOPULMONARY HEMODYNAMICS; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; GAS EXCHANGE; HEART AFTERLOAD; HEART CATHETERIZATION; HEART INDEX; HEART LEFT ATRIUM PRESSURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART RIGHT VENTRICLE DYSPLASIA; HEART RIGHT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART TRANSPLANTATION; HEREDITY; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG HEMODYNAMICS; LUNG PRESSURE; LUNG RESISTANCE; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; MECHANICAL STRESS; MITRAL VALVE REGURGITATION; MITRAL VALVE STENOSIS; MULTICENTER STUDY (TOPIC); NONHUMAN; PATIENT SAFETY; PHYSICAL EXAMINATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCINTIANGIOGRAPHY; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC DYSFUNCTION; SYSTOLIC HEART FAILURE; THERMODILUTION; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TRICUSPID VALVE REGURGITATION;

MANAGEMENT; POST-CAPILLARY PULMONARY HYPERTENSION; PULMONARY HYPERTENSION DUE TO LEFT HEART DISEASE; TRANSPULMONARY GRADIENT;

ANIMALS; HEART DISEASES; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; PULMONARY WEDGE PRESSURE; VASOCONSTRICTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84878268174     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944713477518     Document Type: Article

References (125)

1. Abramson S. Burke J. Kelly J. Jr Kitchen J. III Dougherty M. Yih D. et al. (1992) Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med 116: 888–895.
2. Anand I. McMurray J. Cohn J. Konstam M. Notter T. Quitzau K. et al. (2004) Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364: 347–354.
3. Anderson R. Smerup M. Sanchez-Quintana D. Loukas M. Lunkenheimer P. (2009) The three-dimensional arrangement of the myocytes in the ventricular walls. Clin Anat 22: 64–76.
4. Aronson D. Eitan A. Dragu R. Burger A. (2011) Relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure. Circ: Heart Failure 4: 644–650.
5. Arques S. Roux E. Luccioni R. (2007) Current clinical applications of spectral tissue Doppler echocardiography (E/E’ ratio) as a noninvasive surrogate for left ventricular diastolic pressures in the diagnosis of heart failure with preserved left ventricular systolic function. Cardiovasc Ultrasound 5:16.
6. Auricchio A. Schillinger W. Meyer S. Maisano F. Hoffmann R. Ussia G. et al. (2011) Correction of mitral regurgitation in nonresponders to cardiac resynchronization therapy by MitraClip improves symptoms and promotes reverse remodeling. J Am Coll Cardiol 58: 2183–2189.
7. Aurigemma G. Gaasch W. (2004) Clinical practice. Diastolic heart failure. N Engl J Med 351: 1097–1105.
8. Badesch D.B. Champion H.C. Sanchez M.A. Hoeper M.M. Loyd J.E. Manes A. et al. (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54: S55–S66.
9. Barbieri A. Bursi F. Grigioni F. Tribouilloy C. Avierinos J.F. Michelena H.I. et al. (2011) Prognostic and therapeutic implications of pulmonary hypertension complicating degenerative mitral regurgitation due to flail leaflet: a multicenter long-term international study. Eur Heart J 32: 751–759.
10. Beyersdorf F. Schlensak C. Berchtold-Herz M. Trummer G. (2010) Regression of ‘fixed’ pulmonary vascular resistance in heart transplant candidates after unloading with ventricular assist devices. J Thorac Cardiovasc Surg 140: 747–749.
11. Bhella P. Pacini E. Prasad A. Hastings J. Adams-Huet B. Thomas J. et al. (2011) Echocardiographic indices do not reliably track changes in left-sided filling pressure in healthy subjects or patients with heart failure with preserved ejection fraction. Circ Cardiovasc Imaging 4: 482–489.
12. Bleeker G. Schalij M. Nihoyannopoulos P. Steendijk P. Molhoek S. van Erven L. et al. (2005) Left ventricular dyssynchrony predicts right ventricular remodeling after cardiac resynchronization therapy. J Am Coll Cardiol 46: 2264–2269.
13. Bonow R. Carabello B. Chatterjee K. de Leon A. Jr Faxon D. Freed M. et al. (2008) 2008 focused update incorporated into the ACC / AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 52: e1–142.
14. Bonow R. Carabello B. Kanu C. de Groote L. Jr Faxon D. Freed M. et al. (2006) ACC / AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease). Developed in collaboration with the Society of Cardiovascular Anesthesiologists. Endorsed by the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. Circulation 114: e84–e231.
15. Braun S. Schrotter H. Schmeisser A. Strasser R.H. (2007) Evaluation of pulmonary vascular response to inhaled iloprost in heart transplant candidates with pulmonary venous hypertension. Int J Cardiol 115: 67–72.
16. Braunwald E. Braunwald N. Ross J. Jr Morrow A. (1965) Effects of mitral-valve replacement on the pulmonary vascular dynamics of patients with pulmonary hypertension. N Engl J Med 273: 509–514.
17. Budhiraja R. Tuder R. Hassoun P. (2004) Endothelial dysfunction in pulmonary hypertension. Circulation 109: 159–165.
18. Bursi F. McNallan S. Redfield M. Nkomo V. Lam C. Weston S. et al. (2012) Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol 59: 222–231.
19. Califf R. Adams K. McKenna W. Gheorghiade M. Uretsky B. McNulty S. et al. (1997) A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 134: 44–54.
20. Cappola T. Felker G. Kao W. Hare J. Baughman K. Kasper E. (2002) Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 105: 1663–1668.
21. Champion H. Michelakis E. Hassoun P. (2009) Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation 120: 992–1007.
22. Chang P. Longenecker J. Wang N. Baughman K. Conte J. Hare J. et al. (2005) Mild vs severe pulmonary hypertension before heart transplantation: different effects on posttransplantation pulmonary hypertension and mortality. J Heart Lung Transplant 24: 998–1007.
23. Chen Y. Guo H. Xu D. Xu X. Wang H. Hu X. et al. (2012) Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease. Hypertension 59: 1170–1178.
24. Cody R. Haas G. Binkley P. Capers Q. Kelley R. (1992) Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85: 504–509.
25. Cooper C. Jevnikar F. Walsh T. Dickinson J. Mouhaffel A. Selwyn A. (1998) The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol 82: 609–614.
26. Damy T. Goode K. Kallvikbacka-Bennett A. Lewinter C. Hobkirk J. Nikitin N. et al. (2010) Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. Eur Heart J 31: 2280–2290.
27. de Groote J. Kirkels J. Klopping C. Lahpor J. Caliskan K. Maat A. et al. (2008) Guidelines for heart transplantation. Neth Heart J 16: 79–87.
28. de Groote P. Fertin M. Goeminne C. Petyt G. Peyrot S. Foucher-Hossein C. et al. (2012) Right ventricular systolic function for risk stratification in patients with stable left ventricular systolic dysfunction: comparison of radionuclide angiography to echo Doppler parameters. Eur Heart J 33 (21): 2672–2679.
29. Delgado J. Conde E. Sanchez V. Lopez-Rios F. Gomez-Sanchez M. Escribano P. et al. (2005) Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Failure 7: 1011–1016.
30. de Vita S. Guazzi M. Oreglia J. Guazzi M. (2002) [Alveolar-capillary dysfunction in heart failure]. Ital Heart J Suppl 3: 1022–1026.
31. Di Salvo T. Mathier M. Semigran M. Dec G. (1995) Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 25: 1143–1153.
32. Dokainish H. Nguyen J. Sengupta R. Pillai M. Alam M. Bobek J. et al. (2010) Do additional echocardiographic variables increase the accuracy of E/e’ for predicting left ventricular filling pressure in normal ejection fraction? An echocardiographic and invasive hemodynamic study. J Am Soc Echocardiogr 23: 156–161.
33. Drazner M. Hamilton M. Fonarow G. Creaser J. Flavell C. Stevenson L. (1999) Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant 18: 1126–1132.
34. Enriquez-Sarano M. Rossi A. Seward J. Bailey K. Tajik A. (1997) Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol 29: 153–159.
35. Etz C. Welp H. Tjan T. Hoffmeier A. Weigang E. Scheld H. et al. (2007) Medically refractory pulmonary hypertension: treatment with nonpulsatile left ventricular assist devices. Ann Thorac Surg 83: 1697–1705.
36. Faggiano P. Antonini-Canterin F. Ribichini F. D'Aloia A. Ferrero V. Cervesato E. et al. (2000) Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. Am J Cardiol 85: 204–208.
37. Felker G. O'Connor C. (2001 a) Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 142:393–401.
38. Felker G. O'Connor C. (2001 b) Rational use of inotropic therapy in heart failure. Curr Cardiol Rep 3: 108–113.
39. Fisher M. Forfia P. Chamera E. Housten-Harris T. Champion H. Girgis R. et al. (2009) Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 179: 615–621.
40. Franzen O. van der Heyden J. Baldus S. Schluter M. Schillinger W. Butter C. et al. (2011) MitraClip© therapy in patients with end-stage systolic heart failure. Eur J Heart Failure 13: 569–576.
41. Gaemperli O. Moccetti M. Surder D. Biaggi P. Hurlimann D. Kretschmar O. et al. (2012) Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes. Heart 98: 126–132.
42. Galie N. Hoeper M. Humbert M. Torbicki A. Vachiery J. Barbera J. et al. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30: 2493–2537.
43. Ghio S. Gavazzi A. Campana C. Inserra C. Klersy C. Sebastiani R. et al. (2001) Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 37: 183–188.
44. Giaid A. Saleh D. (1995) Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333: 214–221.
45. Giaid A. Yanagisawa M. Langleben D. Michel R. Levy R. Shennib H. et al. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328: 1732–1739.
46. Grunig E. Barner A. Bell M. Claussen M. Dandel M. Dumitrescu D. et al. (2011) Non-invasive diagnosis of pulmonary hypertension: ESC / ERS Guidelines with Updated Commentary of the Cologne Consensus Conference 2011. Int J Cardiol 154(Suppl. 1): S3–12.
47. Guazzi M. Arena R. (2010) Pulmonary hypertension with left-sided heart disease. Nat Rev Cardiol 7: 648–659.
48. Guazzi M. Boracchi P. Labate V. Arena R. Reina G. (2012 a) Exercise oscillatory breathing and NT-proBNP levels in stable heart failure provide the strongest prediction of cardiac outcome when combining biomarkers with cardiopulmonary exercise testing. J Card Failure 18: 313–320.
49. Guazzi M. Borlaug B. (2012) Pulmonary hypertension due to left heart disease. Circulation 126: 975–990.
50. Guazzi M. Casali M. Berti F. Rossoni G. Colonna V. Guazzi M. (2008) Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation by acute sildenafil in heart failure patients. Clin Pharmacol Ther 83: 336–341.
51. Guazzi M. Myers J. Arena R. (2005) Cardiopulmonary exercise testing in the clinical and prognostic assessment of diastolic heart failure. J Am Coll Cardiol 46:1883–1890.
52. Guazzi M. Pontone G. Brambilla R. Agostoni P. Reina G. (2002) Alveolar–capillary membrane gas conductance: a novel prognostic indicator in chronic heart failure. Eur Heart J 23: 467–476.
53. Guazzi M. Samaja M. Arena R. Vicenzi M. Guazzi M. (2007) Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 50: 2136–2144.
54. Guazzi M. Tumminello G. Di Marco F. Fiorentini C. Guazzi M. (2004) The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 44: 2339–2348.
55. Guazzi M. Vicenzi M. Arena R. (2012 b) Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. Eur J Heart Failure 14: 82–90.
56. Guazzi M. Vicenzi M. Arena R. Guazzi M. (2011) Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124: 164–174.
57. Haddad F. Doyle R. Murphy D. Hunt S. (2008 a) Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation 117: 1717–1731.
58. Haddad F. Hunt S. Rosenthal D. Murphy D. (2008 b) Right ventricular function in cardiovascular disease. Part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation 117: 1436–1448.
59. Haddad F. Kudelko K. Mercier O. Vrtovec B. Zamanian R. de Jesus Perez V. (2011) Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies. Prog Cardiovasc Dis 54: 154–167.
60. Hart S. Krasuski R. Wang A. Kisslo K. Harrison J. Bashore T. (2010) Pulmonary hypertension and elevated transpulmonary gradient in patients with mitral stenosis. J Heart Valve Dis 19: 708–715.
61. Harvey R. Enson Y. Ferrer M. (1971) A reconsideration of the origins of pulmonary hypertension. Chest 59: 82–94.
62. Ho J. Gona P. Pencina M. Tu J. Austin P. Vasan R. et al. (2012) Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. Eur Heart J 33: 1734–1741.
63. Hoeper M. Barbera J. Channick R. Hassoun P. Lang I. Manes A. et al. (2009) Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 54: S85–S96.
64. Howlett J. McKelvie R. Arnold J. Costigan J. Dorian P. Ducharme A. et al. (2009) Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. Can J Cardiol 25: 85–105.
65. Ilsar R. Bailey B. Dobbins T. Celermajer D. (2010) The relationship between pulmonary artery and pulmonary capillary wedge pressure for the diagnosis of pulmonary vascular disease. Heart Lung Circ 19: 38–42.
66. Johnson L. Hapanowicz M. Buonanno C. Bowser M. Marvasti M. Parker F. Jr (1988) Pulmonary hypertension in isolated aortic stenosis. Hemodynamic correlations and follow-up. J Thorac Cardiovasc Surg 95: 603–607.
67. Kalra P. Moon J. Coats A. (2002) Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 85: 195–197.
68. Kapoor N. Varadarajan P. Pai R. (2008) Echocardiographic predictors of pulmonary hypertension in patients with severe aortic stenosis. Eur J Echocardiogr 9: 31–33.
69. Katz S. Balidemaj K. Homma S. Wu H. Wang J. Maybaum S. (2000) Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 36: 845–851.
70. Kerem A. Yin J. Kaestle S. Hoffmann J. Schoene A. Singh B. et al. (2010) Lung endothelial dysfunction in congestive heart failure: role of impaired Ca2+ signaling and cytoskeletal reorganization. Circ Res 106: 1103–1116.
71. Khush K. Tasissa G. Butler J. McGlothlin D. de Marco T. (2009) Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database. Am Heart J 157: 1026–1034.
72. Kind T. Mauritz G. Marcus J. van de Veerdonk N. Vonk-Noordegraaf A. (2010) Right ventricular ejection fraction is better reflected by transverse rather than longitudinal wall motion in pulmonary hypertension. J Cardiovasc Magn Reson 12: 35.
73. Kleber F. Vietzke G. Wernecke K. Bauer U. Opitz C. Wensel R. et al. (2000) Impairment of ventilatory efficiency in heart failure: prognostic impact. Circulation 101: 2803–2809.
74. Kovacs G. Berghold A. Scheidl S. Olschewski H. (2009) Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 34: 888–894.
75. Kurt M. Wang J. Torre-Amione G. Nagueh S. (2009) Left atrial function in diastolic heart failure. Circ Cardiovasc Imaging 2: 10–15.
76. Kuznetsova T. Herbots L. Lopez B. Jin Y. Richart T. Thijs L. et al. (2009) Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Failure 2: 105–112.
77. Lam C. Borlaug B. Kane G. Enders F. Rodeheffer R. Redfield M. (2009 a) Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation 119: 2663–2670.
78. Lam C. Roger V. Rodeheffer R. Borlaug B. Enders F. Redfield M. (2009 b) Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53: 1119–1126.
79. Lepore J. Maroo A. Bigatello L. Dec G. Zapol W. Bloch K. et al. (2005) Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 127: 1647–1653.
80. Levine M. Weinstein J. Diver D. Berman A. Wyman R. Cunningham M. et al. (1989) Progressive improvement in pulmonary vascular resistance after percutaneous mitral valvuloplasty. Circulation 79: 1061–1067.
81. Lewis G. Lachmann J. Camuso J. Lepore J. Shin J. Martinovic M. et al. (2007 a) Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 115: 59–66.
82. Lewis G. Shah R. Pappagianopolas P. Systrom D. Semigran M. (2008) Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone. Circ Heart Failure 1: 227–233.
83. Lewis G. Shah R. Shahzad K. Camuso J. Pappagianopoulos P. Hung J. et al. (2007 b) Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 116: 1555–1562.
84. Lindman B. Zajarias A. Madrazo J. Shah J. Gage B. Novak E. et al. (2012) Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis. Circulation 125: 2353–2362.
85. Lindqvist P. Calcutteea A. Henein M. (2008) Echocardiography in the assessment of right heart function. Eur J Echocardiogr 9: 225–234.
86. Magne J. Lancellotti P. Pierard L.A. (2010) Exercise pulmonary hypertension in asymptomatic degenerative mitral regurgitation. Circulation 122: 33–41.
87. Malouf J. Enriquez-Sarano M. Pellikka P. Oh J. Bailey K. Chandrasekaran K. et al. (2002) Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications. J Am Coll Cardiol 40: 789–795.
88. Marechaux S. Neicu D. Braun S. Richardson M. Delsart P. Bouabdallaoui N. et al. (2011) Functional mitral regurgitation: a link to pulmonary hypertension in heart failure with preserved ejection fraction. J Card Failure 17: 806–812.
89. Martin J. Siegenthaler M. Friesewinkel O. Fader T. van de Loo A. Trummer G. et al. (2004) Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation-a preliminary study. Eur J Cardiothorac Surg 25: 971–977.
90. McQuillan B. Picard M. Leavitt M. Weyman A. (2001) Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 104: 2797–2802.
91. Mehra M. Kobashigawa J. Starling R. Russell S. Uber P. Parameshwar J. et al. (2006) Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates–2006. J Heart Lung Transplant 25: 1024–1042.
92. Meyer P. Filippatos G. Ahmed M. Iskandrian A. Bittner V. Perry G. et al. (2010) Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Circulation 121: 252–258.
93. Mikus E. Stepanenko A. Krabatsch T. Dandel M. Lehmkuhl H. Loforte A. et al. (2011 a) Left ventricular assist device or heart transplantation: impact of transpulmonary gradient and pulmonary vascular resistance on decision making. Eur J Cardiothorac Surg 39: 310–316.
94. Mikus E. Stepanenko A. Krabatsch T. Loforte A. Dandel M. Lehmkuhl H. et al. (2011 b) Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients. Eur J Cardiothorac Surg 40: 971–977.
95. Mullens W. Borowski A. Curtin R. Thomas J. Tang W. (2009) Tissue Doppler imaging in the estimation of intracardiac filling pressure in decompensated patients with advanced systolic heart failure. Circulation 119: 62–70.
96. Naeije R. Vachiery J. Yerly P. Vanderpool R. (2012) The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J 41 (1): 217–223.
97. Nagendran J. Archer S. Soliman D. Gurtu V. Moudgil R. Haromy A. et al. (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116: 238–248.
98. Nagueh S. Middleton K. Kopelen H. Zoghbi W. Quinones M. (1997) Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 30: 1527–1533.
99. Niebauer J. Volk H. Kemp M. Dominguez M. Schumann R. Rauchhaus M. et al. (1999) Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353: 1838–1842.
100. Nielsen E. Smerup M. Agger P. Frandsen J. Ringgard S. Pedersen M. et al. (2009) Normal right ventricular three-dimensional architecture, as assessed with diffusion tensor magnetic resonance imaging, is preserved during experimentally induced right ventricular hypertrophy. Anat Rec (Hoboken ) 292: 640–651.
101. Parker M. Mittleman M. Waksmonski C. Sanders G. Riley M. Douglas P. et al. (2010) Pulmonary hypertension and long-term mortality in aortic and mitral regurgitation. Am J Med 123: 1043–1048.
102. Pokreisz P. Vandenwijngaert S. Bito V. van den Bergh A. Lenaerts I. Busch C. et al. (2009) Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 119: 408–416.
103. Reindl I. Wernecke K. Opitz C. Wensel R. Konig D. Dengler T. et al. (1998) Impaired ventilatory efficiency in chronic heart failure: possible role of pulmonary vasoconstriction. Am Heart J 136: 778–785.
104. Rosario L. Stevenson L. Solomon S. Lee R. Reimold S. (1998) The mechanism of decrease in dynamic mitral regurgitation during heart failure treatment: importance of reduction in the regurgitant orifice size. J Am Coll Cardiol 32: 1819–1824.
105. Rosenkranz S. Behr J. Ewert R. Ghofrani H. Grunig E. Halank M. et al. (2011 a) [Right heart catheterization in pulmonary hypertension]. Dtsch Med Wochenschr 136: 2601–2616.
106. Rosenkranz S. Bonderman D. Buerke M. Felgendreher R. ten Freyhaus H. Grunig E. et al. (2011 b) Pulmonary hypertension due to left heart disease: updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154 Suppl 1: S34–S44.
107. Rossi A. Dini F. Faggiano P. Agricola E. Cicoira M. Frattini S. et al. (2011) Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart 97: 1675–1680.
108. Rudolph V. Knap M. Franzen O. Schluter M. de Vries T. Conradi L. et al. (2011) Echocardiographic and clinical outcomes of MitraClip therapy in patients not amenable to surgery. J Am Coll Cardiol 58: 2190–2195.
109. Rudski L. Lai W. Afilalo J. Hua L. Handschumacher M. Chandrasekaran K. et al. (2010) Guidelines for the echocardiographic assessment of the right heart in adults. A report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 23: 685–713.
110. Saraiva R. Yamano T. Matsumura Y. Takasaki K. Toyono M. Agler D. et al. (2009) Left atrial function assessed by real-time 3-dimensional echocardiography is related to right ventricular systolic pressure in chronic mitral regurgitation. Am Heart J 158: 309–316.
111. Shan X. Quaile M. Monk J. French B. Cappola T. Margulies K. (2012) Differential expression of PDE 5 in failing and nonfailing human myocardium. Circ Heart Failure 5: 79–86.
112. Simonneau G. Galie N. Rubin L. Langleben D. Seeger W. Domenighetti G. et al. (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43: 5S–12S.
113. Solin P. Bergin P. Richardson M. Kaye D. Walters E. Naughton M. (1999) Influence of pulmonary capillary wedge pressure on central apnea in heart failure. Circulation 99: 1574–1579.
114. Szwejkowski B. Elder D. Shearer F. Jack D. Choy A. Pringle S. et al. (2012) Pulmonary hypertension predicts all-cause mortality in patients with heart failure: a retrospective cohort study. Eur J Heart Failure 14: 162–167.
115. Tandon H. Kasturi J. (1975) Pulmonary vascular changes associated with isolated mitral stenosis in India. Br Heart J 37: 26–36.
116. Tedford R. Hassoun P. Mathai S. Girgis R. Russell S. Thiemann D. et al. (2012) Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation 125: 289–297.
117. Tribouilloy C. Rusinaru D. Mahjoub H. Souliere V. Levy F. Peltier M. et al. (2008) Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 29: 339–347.
118. Tryka A. Godleski J. Schoen F. Vandevanter S. (1985) Pulmonary vascular disease and hypertension after valve surgery for mitral stenosis. Hum Pathol 16: 65–71.
119. Vahanian A. Baumgartner H. Bax J. Butchart E. Dion R. Filippatos G. et al. (2007) Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 28: 230–268.
120. Varadarajan P. Pai R. (2012) Prognostic implications of tricuspid regurgitation in patients with severe aortic regurgitation: results from a cohort of 756 patients. Interact Cardiovasc Thorac Surg 14: 580–584.
121. Whitlow P. Feldman T. Pedersen W. Lim D. Kipperman R. Smalling R. et al. (2012) Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol 59: 130–139.
122. Yin J. Kukucka M. Hoffmann J. Sterner-Kock A. Burhenne J. Haefeli W. et al. (2011) Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Circ Heart Failure 4: 198–206.
123. Yock P. Popp R. (1984) Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 70: 657–662.
124. Zimpfer D. Zrunek P. Roethy W. Czerny M. Schima H. Huber L. et al. (2007) Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates. J Thorac Cardiovasc Surg 133: 689–695.
125. Zuern C. Eick C. Rizas K. Stoleriu C. Woernle B. Wildhirt S. et al. (2012) Prognostic value of mild-to-moderate pulmonary hypertension in patients with severe aortic valve stenosis undergoing aortic valve replacement. Clin Res Cardiol 101: 81–88.